TriangleCIML-NK Cells (NCT05580601)
CIML-NK Cells trial for Relapsed/Refractory Acute Myeloid Leukemia (NCT05580601). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for acute myeloid leukemia that has returned or has not responded to treatment, in people 2 and older.
The idea: use natural killer cells from a donor. NK cells are collected from a related, half-matched donor, treated with cytokines to become memory-like cells, and infused into the patient. Eligibility requires at least five percent blasts in the bone marrow.
This phase 1 and 2 study first asks whether the infusion is feasible and safe. At Cincinnati Children's Hospital in Ohio, Zahra Hudda leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.